Minimally Invasive Liver Resection for Early-Stage Hepatocellular Carcinoma: Inconsistent Outcomes from Matched or Weighted Cohorts.
Hepatocellular carcinoma
Minimally invasive surgery
Survival
Journal
Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
ISSN: 1873-4626
Titre abrégé: J Gastrointest Surg
Pays: United States
ID NLM: 9706084
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
received:
28
01
2019
accepted:
28
03
2019
pubmed:
24
4
2019
medline:
15
4
2021
entrez:
24
4
2019
Statut:
ppublish
Résumé
The aim of the current study was to re-evaluate the role of minimally invasive liver resection (MILR) among patients with early-stage (stage I or II) hepatocellular carcinoma (HCC) undergoing partial hepatectomy. A retrospective analysis of the National Cancer Database (NCDB) was conducted to identify patients with early-stage HCC who underwent partial hepatectomy in the USA from 2010 to 2013. Overall survival (OS) was compared in three cohorts: crude; stabilized inverse probability of treatment propensity score weighting (IPTW); and propensity score matching (PSM). Among 4027 patients included in the study, only 11.7%, (n = 473) underwent MILR. In the stabilized IPTW cohort, patients who underwent MILR versus open resection were more likely to have tumors greater than 3 cm (63.9%, n = 285 vs. 51.4%, n = 228, p < 0.001) and poorly/undifferentiated tumors (21.5%, n = 96 vs. 12.9%, n = 57, p < 0.001). Within the crude cohort, a 5-year OS was superior among patients in the open surgical group (67.8%) compared with patients who underwent MILR (56.6%) (p < 0.001). After classic PSM analysis, the 5-year OS of patients undergoing MILR and open surgery were noted to be comparable (57.3% vs 63.8%, p = 0.17; HR 1.16, 95% CI 0.92-1.45). In contrast, after applying IPTW, the 5-year OS of patients who underwent MILR (55.5%) was worse compared with patients who had an open resection (67.5%) (HR 1.46, 95% CI 1.15-1.84; p < 0.001). Long-term outcomes of patients undergoing MILR were comparable with patients who had open surgery when assessed by standard PSM. The use of IPTW resulted in more unbalanced groups leading to residual confounding and bias.
Sections du résumé
BACKGROUND
The aim of the current study was to re-evaluate the role of minimally invasive liver resection (MILR) among patients with early-stage (stage I or II) hepatocellular carcinoma (HCC) undergoing partial hepatectomy.
METHODS
A retrospective analysis of the National Cancer Database (NCDB) was conducted to identify patients with early-stage HCC who underwent partial hepatectomy in the USA from 2010 to 2013. Overall survival (OS) was compared in three cohorts: crude; stabilized inverse probability of treatment propensity score weighting (IPTW); and propensity score matching (PSM).
RESULTS
Among 4027 patients included in the study, only 11.7%, (n = 473) underwent MILR. In the stabilized IPTW cohort, patients who underwent MILR versus open resection were more likely to have tumors greater than 3 cm (63.9%, n = 285 vs. 51.4%, n = 228, p < 0.001) and poorly/undifferentiated tumors (21.5%, n = 96 vs. 12.9%, n = 57, p < 0.001). Within the crude cohort, a 5-year OS was superior among patients in the open surgical group (67.8%) compared with patients who underwent MILR (56.6%) (p < 0.001). After classic PSM analysis, the 5-year OS of patients undergoing MILR and open surgery were noted to be comparable (57.3% vs 63.8%, p = 0.17; HR 1.16, 95% CI 0.92-1.45). In contrast, after applying IPTW, the 5-year OS of patients who underwent MILR (55.5%) was worse compared with patients who had an open resection (67.5%) (HR 1.46, 95% CI 1.15-1.84; p < 0.001).
CONCLUSIONS
Long-term outcomes of patients undergoing MILR were comparable with patients who had open surgery when assessed by standard PSM. The use of IPTW resulted in more unbalanced groups leading to residual confounding and bias.
Identifiants
pubmed: 31012046
doi: 10.1007/s11605-019-04221-0
pii: 10.1007/s11605-019-04221-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
560-568Références
World J Gastroenterol. 2014 Jul 7;20(25):8274-81
pubmed: 25009403
HPB (Oxford). 2015 Oct;17(10):919-26
pubmed: 26234323
Surg Endosc. 2016 May;30(5):1965-74
pubmed: 26194255
Ann Surg. 2017 May;265(5):856-863
pubmed: 27849661
J Minim Invasive Gynecol. 2017 Mar - Apr;24(3):402-406
pubmed: 28011096
Surg Endosc. 2007 Nov;21(11):2004-11
pubmed: 17705086
J Surg Oncol. 2016 Feb;113(2):175-80
pubmed: 26662882
Ann Surg Oncol. 2018 Aug;25(8):2209-2217
pubmed: 29855832
J Clin Oncol. 2018 Feb 20;36(6):600-608
pubmed: 29328861
Ann Surg Oncol. 2018 Mar;25(3):808-817
pubmed: 29302818
JAMA Surg. 2017 Mar 15;152(3):e165059
pubmed: 28052155
J Hepatobiliary Pancreat Sci. 2015 Oct;22(10):721-7
pubmed: 26096910
World J Surg. 2015 Jun;39(6):1474-84
pubmed: 25665675
J Surg Oncol. 2018 Jun;117(7):1517-1530
pubmed: 29473968
Surg Endosc. 2016 Jul;30(7):2975-83
pubmed: 26487215
Eur J Surg Oncol. 2018 Jul;44(7):927-938
pubmed: 29751946
Eur J Surg Oncol. 2015 Jan;41(1):34-9
pubmed: 25468458
BMC Cancer. 2018 Jun 19;18(1):668
pubmed: 29921239
Ann Oncol. 2012 Apr;23(4):903-11
pubmed: 21841155
J Minim Invasive Gynecol. 2014 Sep-Oct;21(5):857-62
pubmed: 24699300
Ann Surg Oncol. 2018 Sep;25(9):2652-2660
pubmed: 29987604
J Clin Epidemiol. 2000 Dec;53(12):1258-67
pubmed: 11146273
Stat Methods Med Res. 2016 Oct;25(5):2214-2237
pubmed: 24463885
Br J Surg. 2016 Jun;103(7):871-80
pubmed: 27029597
Value Health. 2010 Mar-Apr;13(2):273-7
pubmed: 19912596
Ann Surg. 2013 Mar;257(3):506-11
pubmed: 23299521
JAMA Oncol. 2017 Dec 1;3(12):1722-1728
pubmed: 28241198
Multivariate Behav Res. 2011 May;46(3):399-424
pubmed: 21818162
J Hepatol. 2018 Jul;69(1):182-236
pubmed: 29628281
Ann Surg. 2015 Apr;261(4):619-29
pubmed: 25742461
Stat Med. 2015 Dec 10;34(28):3661-79
pubmed: 26238958
Hepatology. 2015 Jan;61(1):191-9
pubmed: 25142309
J Gastrointest Surg. 2016 Sep;20(9):1608-17
pubmed: 27412321
Ann Surg. 2009 Nov;250(5):825-30
pubmed: 19916210
Ann Surg. 2009 Nov;250(5):831-41
pubmed: 19801936
J Surg Oncol. 2017 Jun;115(7):791-804
pubmed: 28205284
Surg Endosc. 2019 Jan;33(1):206-215
pubmed: 29987565
J Hepatol. 2015 Sep;63(3):643-50
pubmed: 25872167
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
Eur J Obstet Gynecol Reprod Biol. 2011 May;156(1):83-6
pubmed: 21269754
Drug Saf. 2017 Feb;40(2):169-181
pubmed: 27900668
BJOG. 2014 Nov;121(12):1538-45
pubmed: 24735243
J Minim Access Surg. 2012 Jul;8(3):67-73
pubmed: 22837592
J Gastrointest Surg. 2016 Nov;20(11):1836-1843
pubmed: 27613735
Ann Surg. 2016 Apr;263(4):761-77
pubmed: 26700223
Obstet Gynecol Surv. 2014 Jul;69(7):426-41
pubmed: 25112591
J Am Coll Surg. 2014 Dec;219(6):1117-23
pubmed: 25442066
Int J Surg. 2013;11(10):1078-82
pubmed: 24129124
Gynecol Oncol. 2015 Oct;139(1):47-51
pubmed: 26166805
Ann Gastroenterol Surg. 2017 Oct 23;2(1):87-94
pubmed: 29863161
Ann Surg. 2016 Oct;264(4):612-20
pubmed: 27433917